HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role

被引：39

作者：

Sanguedolce, Francesca ^{[1
]}

Zanelli, Magda ^{[2
]}

Palicelli, Andrea ^{[2
]}

Bisagni, Alessandra ^{[2
]}

Zizzo, Maurizio ^{[3
]}

Ascani, Stefano ^{[4
]}

Pedicillo, Maria Carmela ^{[1
]}

Cormio, Angelo ^{[5
]}

Falagario, Ugo Giovanni ^{[6
]}

Carrieri, Giuseppe ^{[6
]}

Cormio, Luigi ^{[6
,7
]}

机构：

[1] Univ Foggia, Pathol Unit, Policlin Riuniti, I-71122 Foggia, Italy

[2] Azienda USL IRCCS Reggio Emilia, Pathol Unit, I-42123 Reggio Emilia, Italy

[3] Azienda USL IRCCS Reggio Emilia, Surg Oncol Unit, I-42123 Reggio Emilia, Italy

[4] Univ Perugia, Pathol Unit, Azienda Ospedaliera St Maria Terni, I-05100 Terni, Italy

[5] Univ Politecn Marche, Urol Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, I-60126 Ancona, Italy

[6] Univ Foggia, Dept Urol & Renal Transplantat, Policlin Riuniti, I-71122 Foggia, Italy

[7] Bonomo Teaching Hosp, Dept Urol, I-76123 Andria, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 04期

关键词：

bladder cancer; HER2; immunohistochemistry; diagnosis; prognosis; therapeutic target; TRANSITIONAL-CELL CARCINOMA; FACTOR RECEPTOR 2; UROTHELIAL CARCINOMA; URINARY-BLADDER; IN-SITU; GENE AMPLIFICATION; DIFFERENTIAL-DIAGNOSIS; MOLECULAR SUBTYPES; VARIANT HISTOLOGY; HIGH-RISK;

D O I：

10.3390/ijms24043720

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bladder cancer (BC) is a heterogeneous disease from a molecular, morphological, and clinical standpoint. HER2 is a known oncogene involved in bladder carcinogenesis. Assessing HER2 overexpression as a result of its molecular changes in a routine pathology practice using immunohistochemistry might be a useful adjunct in several scenarios, namely (1) to correctly identify flat urothelial lesions and inverted urothelial lesions in the diagnostic setting; (2) to provide prognostic hints in both non-muscle invasive (NMI) and muscle invasive (MI) tumors, thus supplementing risk stratification tools, especially when evaluating higher-risk tumors such as those with variant morphology; (3) to improve antibody panels as a surrogate marker of BC molecular subtyping. Furthermore, the potential of HER2 as a therapeutic target has been only partly explored so far, in light of the ongoing development of novel target therapies.

引用

页数：14

共 104 条

[1] Computational pathology definitions, best practices, and recommendations for regulatory guidance: a white paper from the Digital Pathology Association [J].